- Home
- ANAB vs RZLV Comparison
ANAB vs RZLV Comparison
Compare ANAB & RZLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- RZLV
- Stock Information
- Founded
- ANAB 2005
- RZLV 2016
- Country
- ANAB United States
- RZLV United Kingdom
- Employees
- ANAB N/A
- RZLV N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- RZLV
- Sector
- ANAB Health Care
- RZLV
- Exchange
- ANAB Nasdaq
- RZLV NYSE
- Market Cap
- ANAB 621.1M
- RZLV 514.1M
- IPO Year
- ANAB 2017
- RZLV N/A
- Fundamental
- Price
- ANAB $23.17
- RZLV $1.92
- Analyst Decision
- ANAB Buy
- RZLV Strong Buy
- Analyst Count
- ANAB 10
- RZLV 5
- Target Price
- ANAB $44.25
- RZLV $5.20
- AVG Volume (30 Days)
- ANAB 775.6K
- RZLV 3.5M
- Earning Date
- ANAB 08-04-2025
- RZLV 02-21-2025
- Dividend Yield
- ANAB N/A
- RZLV N/A
- EPS Growth
- ANAB N/A
- RZLV N/A
- EPS
- ANAB N/A
- RZLV N/A
- Revenue
- ANAB $111,872,000.00
- RZLV $187,788.00
- Revenue This Year
- ANAB N/A
- RZLV $18,916.66
- Revenue Next Year
- ANAB $24.39
- RZLV $175.14
- P/E Ratio
- ANAB N/A
- RZLV N/A
- Revenue Growth
- ANAB 387.20
- RZLV 29.46
- 52 Week Low
- ANAB $12.21
- RZLV $1.07
- 52 Week High
- ANAB $41.31
- RZLV $12.29
- Technical
- Relative Strength Index (RSI)
- ANAB 56.01
- RZLV N/A
- Support Level
- ANAB $22.46
- RZLV N/A
- Resistance Level
- ANAB $24.17
- RZLV N/A
- Average True Range (ATR)
- ANAB 1.72
- RZLV 0.00
- MACD
- ANAB -0.01
- RZLV 0.00
- Stochastic Oscillator
- ANAB 73.23
- RZLV 0.00
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About RZLV REZOLVE AI LTD
Rezolve AI PLC is an AI-powered solutions company, specializing in enhancing customer engagement, operational efficiency, and revenue growth for the retail and e-commerce sectors. The company's product, Brain Commerce, powered by its proprietary Large Language Model (LLM) brainpowa, transforms the online shopping experience. By surpassing traditional site search and product discovery tools, Brain Commerce improves conversion rates, increases average order value (AOV), and reduces cart abandonment. The company has one reportable segment, which is cloud-based services. Geographically, the company generates revenue from Canada, the United States, Mexico, Australia, the United Kingdom, and Japan, with the majority of revenue generated from the United States.